Patisiran pregnancy safety monitoring program
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This program monitors the safety of the drug patisiran during pregnancy. If you have received patisiran around the time of pregnancy, it may help track any effects on you and your baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been exposed to the drug patisiran (used for ATTR amyloidosis) at any time from 12 weeks before your last menstrual period or at any point during pregnancy.
- If you are in Germany, you must be receiving treatment according to the approved prescribing information for ATTR amyloidosis.
- There are no other requirements or restrictions to join this program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the safety of the medicine TEGSEDI during pregnancy for women with hATTR-PN, a rare genetic nerve condition. It compares outcomes between those who took TEGSEDI while pregnant and those who did not, to better understand any risks.
This trial tests a new medicine called nucresiran for people with a rare genetic nerve condition (hATTR-PN). The goal is to see if it can slow down or improve nerve damage.
This trial tests whether the drug tafamidis can help people with a specific type of nerve damage caused by abnormal protein buildup. It aims to slow or improve symptoms in adults with this condition.
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
This study tracks the safety of eplontersen during pregnancy and breastfeeding by collecting reports from people who have taken it. It helps doctors understand any risks to the baby or mother.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
Hear when a new Hereditary Transthyretin-mediated (hATTR) Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.